ML Caramori, M Mauer - Current opinion in nephrology and hypertension, 2003 - journals.lww.com Recent findings: There have been advances in the understanding of diabetic
nephropathy pathology. Clearly, structural changes may be advanced before any
clinical findings are apparent. Not all functional consequences of the ... Cited by 68 - Related articles - BL Direct - All 7 versions
A Meirhaeghe, P Amouyel - Molecular Genetics and Metabolism, 2004 - Elsevier Peroxisome proliferator-activated receptor γ (PPARγ) is a transcription factor
with a key role in adipocyte differentiation. Since 1997, studies of rare
mutations and common polymorphisms of the PPARγ gene have enabled us to ... Cited by 64 - Related articles - All 3 versions
ML Caramori, LH Canani, LA Costa, JL Gross - Diabetes, 2003 - Am Diabetes Assoc The peroxisome proliferator-activated receptor γ2 (PPARγ2) Pro12Ala
polymorphism has been associated with a decreased risk of type 2 diabetes and a
lower albumin excretion rate (AER) in patients with established diabetes. ... Cited by 43 - Related articles - BL Direct - All 4 versions
KG Ewens, RA George, K Sharma, FN … - Diabetes, 2005 - Am Diabetes Assoc Several lines of evidence, including familial aggregation, suggest that allelic
variation contributes to risk of diabetic nephropathy. To assess the evidence
for specific susceptibility genes, we used the transmission/disequilibrium ... Cited by 34 - Related articles - BL Direct - All 5 versions
R Agarwal, C Saha, M Battiwala, N Vasavada … - Kidney international, 2005 - nature.com Diabetic nephropathy progresses relentlessly to end-stage renal disease (ESRD).
Animal experiments have found that peroxisome proliferator activated receptor-
(PPAR- )–based therapy can have a glucose independent effect on renal ... Cited by 32 - Related articles - All 4 versions
- ►diabetesjournals.org S Hadjadj, F Péan, Y Gallois, P Passa, R … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—The insulin resistance score of relatives was positively correlated
with the albumin excretion rate (P = 0.0009) and fasting plasma glucose (P =
0.0003) and HbA 1c (P < 0.0001) concentrations. This score was higher in ... Cited by 25 - Related articles - BL Direct - All 6 versions
- ►nih.gov N Kimura, R Oda, Y Inaki, O Suzuki - Nucleic Acids Research, 2004 - Oxford Univ Press Oligonucleotide-based DNA microarrays are becoming increasingly useful tools for
the analysis of gene expression and single nucleotide polymorphisms (SNPs).
Here, we present a method that permits the manufacture of microarrays from ... Cited by 17 - Related articles - BL Direct - All 7 versions
F Ye, ZS Zhang, HB Luo, JH Shen, KX Chen, … - Chembiochem, 2006 - interscience.wiley.com The peroxisome proliferator-activated receptor (PPAR ) is an important
therapeutic drug target for several conditions, including diabetes,
inflammation, dyslipidemia, hypertension, and cancer. It is shown that an ... Cited by 17 - Related articles - BL Direct - All 4 versions
MI Yilmaz, A Sonmez, K Caglar, DE Gok, T … - Endocrine, 2004 - Springer Received September 10, 2004; Revised November 19, 2004; Accepted December 6,
2004. Author to whom all correspondence and reprint requests should be
addressed: M. Ilker Yilmaz, MD, Department of Nephrology, Gülhane School ... Cited by 16 - Related articles - All 2 versions
JC Florez - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc The peroxisome proliferator-activated receptor- (PPAR ) is a ligand-activated
transcription factor involved in lipid and glucose metabolism, fatty acid
transport, and adipocyte differentiation (1). In 1997, Yen et al. (2) ... Cited by 13 - Related articles - All 4 versions
